What is this study trying to find out about unexplained female infertility?

This study is investigating whether biological aging markers, especially telomere profiles, can identify causes of infertility in women who have not conceived despite treatment. It also evaluates if a personalized integrative therapy combining Traditional Chinese Medicine and nutritional support can improve pregnancy chances. The study is led by BEYOND GENOMiX SA, AG, Ltd to explore new molecular approaches to infertility.

Who may be eligible for this infertility clinical trial?

Women aged 25 to 42 years with a diagnosis of unexplained infertility after at least 12 months of trying and repeated assisted reproductive technology failures may be eligible. Participants must be female and willing to undergo aging biomarker testing and integrative therapy. Current pregnancy, breastfeeding, or certain genetic conditions exclude participation. Please review eligibility criteria for more details.

Is there any cost to participate in this infertility clinical trial?

Study-related care, including all study procedures, testing, and integrative treatment, is provided at no cost. However, personal travel expenses or other indirect costs may vary and are not guaranteed to be covered. Participants should plan accordingly for any travel or time commitments.

Actively Recruiting

Phase Not Applicable

Age: 25Years - 42Years

FEMALE

ID07404969

Study of Telomere and Biological Aging Markers to Guide Personalized Traditional Chinese and Conventional Medicine Treatment in Women With Persistent Unexplained Infertility After Prior Treatments

Led by BEYOND GENOMiX SA, AG, Ltd · Updated on 2026-04-29

Participants Needed

Research Sites

13 weeks

Total Duration

AI-Summary

What this Trial Is About

This research aims to explore whether profiling telomeres and other biological aging markers can reveal underlying causes of persistent infertility in women who have undergone treatment but remain unable to conceive. The study focuses on women aged 25 to 42 years with unexplained infertility despite proper management of known reproductive issues and repeated assisted reproductive technology ART attempts. It seeks to understand if these molecular aging indicators can define a biological aging pattern related to infertility and whether personalized integrative treatments can improve pregnancy outcomes. Participants receive baseline reproductive evaluations and blood tests to assess telomere length and aging hallmarks at the cellular level. The intervention includes a personalized integrative approach combining Traditional Chinese Medicine TCM herbal formulas and targeted nutritional supplements aimed at restoring cellular aging markers. This preconception phase lasts between 4 and 12 weeks, after which women attempt conception naturally or with ART such as intrauterine insemination IUI or in vitro fertilization IVF, while continuing integrative support. Throughout the study, participants undergo ongoing assessments of reproductive health, molecular aging markers, and pregnancy outcomes for up to 12 months. Researchers monitor changes in telomere length, the proportion of critically short telomeres, ovarian reserve markers, and overall safety and tolerability of the intervention. The main outcome is clinical pregnancy rate per conception attempt, with secondary measures evaluating molecular and reproductive changes related to the integrative therapy.

CONDITIONS

Brief Title

Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility

Who Can Participate

Age: 25Years - 42Years

FEMALE

Eligibility Criteria

You may qualify if you...

Biological female participants aged 25 to 42 years
Diagnosis of infertility defined as failure to conceive after at least 12 months of unprotected intercourse and/or repeated failure of assisted reproductive technologies (ART), including intrauterine insemination (IUI) and/or in vitro fertilization (IVF)
History of post-treatment unexplained or functionally idiopathic infertility despite adequate correction of identifiable reproductive conditions
Eligibility for natural conception attempts and/or assisted reproductive technologies according to routine clinical practice
Willingness to undergo biological aging biomarker profiling including leukocyte telomere analysis
Ability and willingness to comply with study procedures including the preconception integrative intervention and follow-up assessments
Provision of written informed consent prior to participation

You will not qualify if you...

Current pregnancy or breastfeeding at the time of enrollment
Known chromosomal abnormalities or genetic conditions directly impairing fertility such as Turner syndrome
Untreated severe male factor infertility preventing conception by natural or standard ART methods
Active malignancy or history of cancer requiring systemic treatment within the past 5 years
Severe systemic disease or medical condition contraindicating pregnancy or ART participation
Use of investigational drugs or participation in another interventional clinical trial that could interfere with study outcomes
Known hypersensitivity or contraindication to components of the integrative intervention
Any condition that would interfere with safe participation or interpretation of study results as judged by the investigator

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Baseline Assessment

Duration - Up to 1 week

Participants undergo comprehensive reproductive evaluation and molecular profiling including leukocyte telomere analysis to establish individual biological aging signatures relevant to fertility.

1 baseline visit (in-person)

Preconception Integrative Intervention

Duration - 4 to 12 weeks

Participants receive a personalized 4 to 12-week integrative treatment combining Traditional Chinese Medicine herbal formulations and targeted nutraceutical supplementation to restore telomere stability, improve mitochondrial function, and reduce cellular senescence in support of reproductive health.

Weekly visits for up to 12 weeks

Conception Attempt

Duration - Up to 12 months

Participants attempt to conceive naturally or via assisted reproductive technologies such as intrauterine insemination (IUI) or in vitro fertilization (IVF) while continuing integrative therapy to maintain molecular improvements and support fertility.

Visits as per routine fertility care for natural conception or ART cycles

Follow-up and Outcome Assessment

Duration - Up to 12 months

Participants are monitored for clinical pregnancy outcomes and undergo follow-up assessments of molecular and reproductive parameters to evaluate the effectiveness and safety of the integrative intervention over a period of up to 12 months.

Approximately 3 to 6 visits depending on biological response and clinical progress